Archives
-
PreScission Protease for Nuclear Biology
2026-09-12
PreScission Protease enables precise fusion protein tag cleavage before localization and chromatin assays. This article explains how HRV 3C protease can improve construct interpretation while connecting protein purification decisions to evidence from Drosophila Keap1–lamin research.
-
Carrier-Platin and the ROS Storm in Cancer Cells
2026-09-11
The Biomaterials study introduces carrier-platin, a poly(amino acid) formulation containing ultrasmall platinum nanoparticles that produces a rapid intracellular ROS burst. The resulting cancer-cell death occurs within approximately 30 minutes, is distinct from apoptosis and ferroptosis, and remains independent of DNA damage, suggesting a potential strategy for drug-resistant tumors.
-
Thymoquinone Protects Against Doxorubicin Cardiotoxicity
2026-09-11
A 2025 mouse study reports that thymoquinone reduces doxorubicin-induced cardiac injury, with protection associated with improved cardiac function, redox balance, mitochondrial structure, and Nrf2/HO-1 signaling. The findings position thymoquinone as a useful preclinical probe for investigating oxidative stress and ferroptosis-related mechanisms, while pathway causality and clinical translation remain unresolved.
-
Cy5 Hydrazide for Protein Carbonyl Labeling
2026-09-10
Cy5 hydrazide is a carbonyl-reactive fluorescent dye for aldehyde and ketone biomolecule labeling, including protein carbonylation labeling after oxidative stress. Its red-shifted 646 nm excitation and 662 nm emission support fluorescence detection after SDS-PAGE, but its low aqueous solubility requires preparation in an organic co-solvent.
-
Cy3-UTP for RNA Nanoparticle Assays
2026-09-10
Cy3-UTP converts in vitro-transcribed RNA into a direct fluorescent readout for particle stability, cellular uptake, and RNA–protein interactions. This workflow connects molecular labeling with the structure–function questions raised by modern ternary RNA nanoparticle engineering.
-
10074-G5: Mechanism-Led MYC Assay Design
2026-09-09
Explore how 10074-G5 functions as a c-Myc inhibitor and how the miR-196a/TERT/NFκB findings refine assay design. This guide connects molecular perturbation, orthogonal phenotyping, and translational interpretation without treating cell-line potency as a universal predictor.
-
Aurora Kinase A in High-Risk Retinoblastoma
2026-09-09
A 2024 study identifies Aurora kinase A (AURKA) overexpression as a frequent feature of human retinoblastoma and links it to histopathologic factors associated with aggressive disease and poor chemotherapy response. By combining patient-tissue analysis with genetic depletion, pharmacologic inhibition, patient-derived models, xenografts, and enucleated specimens, the work provides a translational rationale for evaluating AURKA as a target in advanced retinoblastoma.
-
UK-5099 in Immunometabolic Assay Design
2026-09-08
UK-5099 enables researchers to isolate mitochondrial pyruvate entry from broader metabolic effects in immune, endocrine, and whole-animal models. This practical guide connects MPC inhibition with standardized whole-blood stimulation, respiration measurements, insulin-secretion workflows, and reproducibility-focused troubleshooting.
-
γH2AX DNA Damage Detection Kit for FLASH-RT
2026-09-08
Use γH2AX imaging to connect radiosensitizer exposure with DNA double-strand break formation, cell death, and repair kinetics. This workflow shows how the red-fluorescent kit can complement viability, apoptosis, and immune-readout experiments in FLASH-RT and broader genotoxicity studies.
-
High Viscosity, P-gp, and Cancer Chemoresistance
2026-09-07
The reference study identifies extracellular fluid viscosity as a mechanical cue that can promote doxorubicin resistance through a membrane-tension–TRPV4–YAP pathway and increased P-glycoprotein expression. Its findings connect tumor-fluid mechanics with drug efflux biology and suggest experimental strategies for separating upstream mechanotransduction from transporter-dependent resistance.
-
Calpain Inhibitor II, ALLM: Protease Assay Guide
2026-09-07
Calpain Inhibitor II, ALLM is a cell-permeable tool for probing calpain- and cathepsin-dependent proteolysis, apoptosis, and FAK stability. This workflow guide connects practical dosing and controls with leukemia, lymphoma, and triple-negative breast cancer use cases while emphasizing its broad target profile.
-
Leucomycin (Kitasamycin) Assay Workflows
2026-09-05
Leucomycin supports both whole-cell bacterial growth inhibition assays and cell-free translation experiments, making it useful for separating ribosome-level potency from uptake effects. Its multi-component kitasamycin profile also enables component-aware antibacterial drug discovery, resistance testing, and biosynthesis studies.
-
Cyclic Pifithrin-α hydrobromide Workflows
2026-09-04
Cyclic Pifithrin-α hydrobromide is a practical p53 inhibitor for separating p53-dependent apoptosis and growth arrest from broader DNA-damage effects. This guide shows how to formulate, dose, control, and troubleshoot the compound in cancer, irradiation, and neuroinflammation-oriented assays.
-
Triacetin Workflows for Cancer and Metabolic Research
2026-09-04
Triacetin, or glyceryl triacetate, supports mechanism-aware glioblastoma, metabolic, and ocular workflows in one versatile reagent platform. This guide connects dose selection, vehicle control, orthogonal readouts, and troubleshooting to practical experimental decisions.
-
SR-202: A Causal Lens on PPARγ Biology
2026-09-03
SR-202 is a selective PPARγ antagonist for resolving how nuclear-receptor signaling shapes adipogenesis, insulin resistance, and macrophage inflammation. This article presents a causal assay framework that distinguishes receptor dependence from cell-state effects, extending its value across metabolic and intestinal inflammation research.